OGN Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of 9.99% compared to Organon & Co.'s net margin of 33.68%. Organon & Co.'s return on equity of 79.63% beat Merck & Co., Inc.'s return on equity of 39.63%.

Organon & Co. has a consensus price target of $9.36, signalling upside risk potential of 31.98%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 4.76%. Given that Organon & Co. has higher upside potential than Merck & Co., Inc., analysts believe Organon & Co. is more attractive than Merck & Co., Inc..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.8%. Merck & Co., Inc. offers a yield of 3.12% to investors and pays a quarterly dividend of $0.85 per share. Organon & Co. pays 33.59% of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Organon & Co.'s net income of $160M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Organon & Co.'s price-to-earnings ratio is 3.69x while Merck & Co., Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.29x versus 4.14x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 9.99% compared to Organon & Co.'s net margin of 38.89%. Organon & Co.'s return on equity of 79.63% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Organon & Co. has a consensus price target of $9.36, signalling upside risk potential of 31.98%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 0.6%. Given that Organon & Co. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Organon & Co. is more attractive than Regeneron Pharmaceuticals, Inc..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.8%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Organon & Co. pays 33.59% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Organon & Co.'s net income of $160M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Organon & Co.'s price-to-earnings ratio is 3.69x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.29x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rockwell Medical, Inc. has a net margin of 9.99% compared to Organon & Co.'s net margin of -11.01%. Organon & Co.'s return on equity of 79.63% beat Rockwell Medical, Inc.'s return on equity of -17.16%.

Organon & Co. has a consensus price target of $9.36, signalling upside risk potential of 31.98%. On the other hand Rockwell Medical, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 359.62%. Given that Rockwell Medical, Inc. has higher upside potential than Organon & Co., analysts believe Rockwell Medical, Inc. is more attractive than Organon & Co..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rockwell Medical, Inc. has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.123%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.8%. Rockwell Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & Co. pays 33.59% of its earnings as a dividend. Rockwell Medical, Inc. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are larger than Rockwell Medical, Inc. quarterly revenues of $15.9M. Organon & Co.'s net income of $160M is higher than Rockwell Medical, Inc.'s net income of -$1.8M. Notably, Organon & Co.'s price-to-earnings ratio is 3.69x while Rockwell Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.29x versus 0.37x for Rockwell Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 9.99% compared to Organon & Co.'s net margin of 42.36%. Organon & Co.'s return on equity of 79.63% beat United Therapeutics Corp.'s return on equity of 19.2%.

Organon & Co. has a consensus price target of $9.36, signalling upside risk potential of 31.98%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 1.53%. Given that Organon & Co. has higher upside potential than United Therapeutics Corp., analysts believe Organon & Co. is more attractive than United Therapeutics Corp..

Organon & Co. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Organon & Co. has a quarterly dividend of $0.02 per share corresponding to a yield of 4.8%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & Co. pays 33.59% of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & Co. quarterly revenues are $1.6B, which are larger than United Therapeutics Corp. quarterly revenues of $799.5M. Organon & Co.'s net income of $160M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Organon & Co.'s price-to-earnings ratio is 3.69x while United Therapeutics Corp.'s PE ratio is 19.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & Co. is 0.29x versus 7.87x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.